Perceptions, Expectations, Preferences, and Attitudes Toward Premature Ejaculation, Its Diagnosis and Topical Treatment with Fortacin™ Spray: Results from an Expert Panel Discussion

Introduction Premature ejaculation (PE) represents the most prevalent male sexual issue. Before beginning treatment, it is essential to discuss the patient’s expectations thoroughly. Methods Herein, we report the results of an expert panel discussion about perceptions, expectations, preferences, and attitudes towards PE, its diagnosis and treatment. The panel took place in October 2019 and involved 30 Italian urologists experienced in the management of male sexual dysfunction. It aimed at investigating physicians’ points of view about selected aspects of PE management which emerged during the counselling of PE patients over the previous two years. Treatment-related questions were mainly focused on topical treatment with Fortacin™. Results Overall, 83.3% of those interviewed declared that most of their patients perceive PE as a bother rather than a disease. The percentage of urologists interviewed perceived that improved subjective control over ejaculation and prolonged intravaginal ejaculatory latency time (IELT) as the main benefit expected by the majority of their patients was 56.5% and 10%, respectively. Eighty percent of urologists reported on-demand regimen as the dosage modality preferred by the majority of their patients and half of them reported the topical route to be the way of administration preferred in most cases. Moreover, 73.3% of urologists reported that adherence to treatment was higher in patients undergoing topical treatment. Finally, 80% of urologists perceived Fortacin to be efficacious in patients with acquired PE and 70% of them perceived its efficacy to be independent from IELT. Discussion Most patients perceive PE as a bother rather than a disease and mainly advocate an improved control over ejaculation. Fortacin is perceived as efficacious in patients with acquired PE, and independent from IELT.

[1]  A. Burri,et al.  Novel Treatment for Premature Ejaculation in the Light of Currently Used Therapies: A Review. , 2019, Sexual medicine reviews.

[2]  M. Butcher,et al.  Topical Agents for Premature Ejaculation: A Review. , 2019, Sexual medicine reviews.

[3]  A. Burri,et al.  Fortacin™ Spray for the Treatment of Premature Ejaculation , 2017, Urologia.

[4]  Tae Nam Kim,et al.  Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: A 2-Year Prospective Observational Study , 2016, Sexual medicine.

[5]  D. Moon,et al.  Diagnosis and Treatment of Premature Ejaculation by Urologists in South Korea , 2016, The world journal of men's health.

[6]  W. Hellstrom,et al.  The pathophysiology of acquired premature ejaculation , 2016, Translational andrology and urology.

[7]  C. McMahon Emerging and investigational drugs for premature ejaculation , 2016, Translational andrology and urology.

[8]  G. Puppo,et al.  Comprehensive review of the anatomy and physiology of male ejaculation: Premature ejaculation is not a disease , 2016, Clinical anatomy.

[9]  P. Santtila,et al.  Antidepressant treatment of premature ejaculation: discontinuation rates and prevalence of side effects for dapoxetine and paroxetine in a naturalistic setting , 2014, International Journal of Impotence Research.

[10]  T. Cai,et al.  Dapoxetine treatment in patients with lifelong premature ejaculation: the reasons of a "Waterloo". , 2013, Urology.

[11]  N. Longo,et al.  Ejaculatory Abstinence Influences Intravaginal Ejaculatory Latency Time: Results from a Prospective Randomized Trial , 2012, Urologia Internationalis.

[12]  C. McMahon,et al.  Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. , 2011, The journal of sexual medicine.

[13]  S. Bull,et al.  Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials. , 2010, The journal of sexual medicine.

[14]  Francesco Montorsi,et al.  Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. , 2010, European urology.

[15]  D. Patrick,et al.  Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine , 2008, BJU international.

[16]  W. Hellstrom,et al.  An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. , 2008, The journal of sexual medicine.

[17]  D. Revicki,et al.  Characterizing the burden of premature ejaculation from a patient and partner perspective: a multi-country qualitative analysis , 2008, Health and quality of life outcomes.

[18]  C. Nelson,et al.  Urologist practice patterns in the management of premature ejaculation: a nationwide survey. , 2008, The journal of sexual medicine.

[19]  M. Wyllie,et al.  A review of the current status of topical treatments for premature ejaculation , 2007, BJU international.

[20]  A. Zwinderman,et al.  The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. , 2007, The journal of sexual medicine.

[21]  D. Patrick,et al.  Interrelationships among measures of premature ejaculation: the central role of perceived control. , 2007, The journal of sexual medicine.

[22]  W. Hellstrom,et al.  Treatment of premature ejaculation: new drugs and treatment strategies , 2006 .

[23]  G. Broderick Premature ejaculation: on defining and quantifying a common male sexual dysfunction. , 2006, The journal of sexual medicine.

[24]  W. Hellstrom Current and future pharmacotherapies of premature ejaculation. , 2006, The journal of sexual medicine.

[25]  P. Quinn,et al.  A multinational population survey of intravaginal ejaculation latency time. , 2005, The journal of sexual medicine.

[26]  I. Sharlip Diagnosis and treatment of premature ejaculation: the physician's perspective. , 2005, The journal of sexual medicine.

[27]  W. Busato,et al.  Topical anaesthetic use for treating premature ejaculation: a double‐blind, randomized, placebo‐controlled study , 2004, BJU international.

[28]  I. Geçit,et al.  Optimum usage of prilocaine‐lidocaine cream in premature ejaculation , 2002, Andrologia.